Co-infections and superinfections complicating COVID-19 in cancer patients: A multicentre, international study

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Gudiol, C (Author) Other; Dura Miralles, X (Author) Other; Aguilar Company, J (Author) Other; Hernandez Jimenez, P (Author) Other; Martinez Cutillas, M (Author) Other; Fernandez Aviles, F (Author) Other; Machado, M (Author) Other; Vazquez, L (Author) Other; Martin Davila, P (Author) Other; de Castro, N (Author) Other; Abdala, E (Author) Other; Sorli, L (Author) Other; Andermann, TM (Author) Other; Marquez Gomez, I (Author) Other; Morales, H (Author) Other; Gabilan, F (Author) Other; Ayaz, CM (Author) Other; Kayaaslan, B (Author) Other; Aguilar Guisado, M (Author) Other; Herrera, F (Author) Other; Royo Cebrecos, C (Author) Other; Peghin, M (Author) Other; Gonzalez Rico, C (Author) Other; Goikoetxea, J (Author) Other; Salgueira, C (Author) Other; Silva Pinto, A (Author) FMUP; Gutierrez Gutierrez, B (Author) Other; Cuellar, S (Author) Other; Haidar, G (Author) Other; Maluquer, C (Author) Other; Marin, M (Author) Other; Pallares, N (Author) Other; Carratala, J (Author) Other

Journal

Title: Journal of Infection

Vol. 83

Pages: 306-313

ISSN: 0163-4453

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 9 Citations

Scopus - 10 Citations

Other information

Authenticus ID: P-00V-BX8

DOI: 10.1016/j.jinf.2021.07.014

Abstract (EN): Background: We aimed to describe the epidemiology, risk factors, and clinical outcomes of co-infections and superinfections in onco-hematological patients with COVID-19. Methods: International, multicentre cohort study of cancer patients with COVID-19. All patients were included in the analysis of co-infections at diagnosis, while only patients admitted at least 48 h were included in the analysis of superinfections. Results: 684 patients were included (384 with solid tumors and 300 with hematological malignancies). Co-infections and superinfections were documented in 7.8% (54/684) and 19.1% (113/590) of patients, respectively. Lower respiratory tract infections were the most frequent infectious complications, most often caused by Streptococcus pneumoniae and Pseudomonas aeruginosa. Only seven patients developed opportunistic infections. Compared to patients without infectious complications, those with infections had worse outcomes, with high rates of acute respiratory distress syndrome, intensive care unit (ICU) admission, and case-fatality rates. Neutropenia, ICU admission and high levels of C-reactive protein (CRP) were independent risk factors for infections. Conclusions: Infectious complications in cancer patients with COVID-19 were lower than expected, affecting mainly neutropenic patients with high levels of CRP and/or ICU admission. The rate of opportunistic infections was unexpectedly low. The use of empiric antimicrobials in cancer patients with COVID-19 needs to be optimized. (C) 2021 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association.

Language: English

Type (Professor's evaluation): Dissemination

No. of pages: 8